-- Saturday, September 17, 2022, 19:53 --
Company Profile: |
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts. |
Recent News: |
The company reported that total revenue for the second quarter of 2022 was $29.6 million compared to $19.6 million for the same period in the prior year. |
|
Fundamental Analysis: |
Ninestocks analyzes several different financial aspects: |
Price to Book Value – P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. @@@@@ |
Price to Earnings – PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). @@@@@ |
Discounted cash flow – DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. @@@@@ |
Return on Assets – ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. @@@@@ |
Return on Equity – ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. @@@@@ |
Debt to Equity – evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. @@@@@ |
Conclusion: |
PRTK receives outperform rating in discounted cash flow and debt to equity. Technical indicators signal the bullish signs, as there is a bullish crossover in the MACD and the stochastic oscillator and the RSI(14) stands at 53.8 with positive bias. We rate Paratek Pharmaceuticals, Inc. (PRTK) a STRONG BUY. |